Pricing Log in Create free account

Inhibrx Biosciences, Inc. (INBX) vs Verastem, Inc. (VSTM)

Inhibrx Biosciences, Inc. and Verastem, Inc. are both Biotechnology companies. Inhibrx Biosciences, Inc. and Verastem, Inc. are of similar size ($1.2B and $1.1B). Inhibrx Biosciences, Inc. has the higher net margin (0.00% vs −178.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Inhibrx Biosciences, Inc. leads on 10 and Verastem, Inc. on 4.

Valuation

Metric INBX VSTM Biotechnology median
P/E n/m n/m 10.60
P/S 424.97 8.51 9.40
P/B n/m 84.49 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 438.60 7.98 9.02
Earnings yield (10.39%) (21.95%) (32.88%)
Free cash flow yield (9.85%) (18.70%) (23.13%)

Profitability

Metric INBX VSTM Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin 0.00% (193.73%) 0.00%
Net margin 0.00% (178.38%) 0.00%
Free cash flow margin 0.00% (159.10%) 0.00%
Return on equity (1,773.60%) 6,595.50% (51.96%)
Return on assets (75.44%) (88.02%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric INBX VSTM Biotechnology median
Revenue growth (TTM) — 286.13% 6.76%
EPS growth (last fiscal year) (108.03%) 17.49% 29.88%
Revenue growth, 5-year CAGR — 12.11% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric INBX VSTM Biotechnology median
Debt to equity (3.33) 11.82 0.00
Current ratio 5.07 1.93 4.97
Net debt to EBITDA 0.18 0.76 1.01

Dividend

Metric INBX VSTM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INBX VSTM Biotechnology median
Market cap 1.18b 1.14b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack